Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-induced MICA/B expression

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Xu, Xiulong ^a   Rao, Geetha S ^a   Groh, Veronika ^b   Spies, Thomas ^b   Gattuso, Paolo ^a   Kaufman, Howard L ^a   Plate, Janet ^a   Prinz, Richard A ^a,c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

DNA damage; Pancreatic cancerMICA bgemcitabineuric acidallopurinol

Indexed keywords

ALLOPURINOL; FLUOROURACIL; GEMCITABINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 RELATED CHAIN A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 RELATED CHAIN B; UNCLASSIFIED DRUG; URIC ACID; XANTHINE; XANTHINE OXIDASE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; HLA ANTIGEN CLASS 1; MHC CLASS I RELATED CHAIN A; MHC CLASS I-RELATED CHAIN A; MICB ANTIGEN; XANTHINE DEHYDROGENASE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL KILLING; CHROMIUM 51 RELEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS DUCT; TISSUE LEVEL; BLOOD; CELL DEATH; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFECT; GALLBLADDER TUMOR; GENE EXPRESSION; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; NATURAL KILLER CELL; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PERITONEUM TUMOR; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CELL DEATH; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DEOXYCYTIDINE; DNA DAMAGE; FEMALE; GALLBLADDER NEOPLASMS; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; URIC ACID; XANTHINE DEHYDROGENASE;

EID: 79956204623     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-194     Document Type: Article

References (39)

1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004, 363:1049-1057. 10.1016/S0140-6736(04)15841-8, 3062508, 15051286.
2. Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003, 9:269-277. 10.1038/nm0303-269, 12612576.
3. Dranoff G. Coordinated tumor immunity. J Clin Invest 2003, 111:1116-1118. 152946, 12697728.
4. Bahram S. MIC genes: from genetics to biology. Adv Immunol 2000, 76:1-60.
5. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003, 3:781-790. 10.1038/nri1199, 14523385.
6. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999, 96:6879-6884. 10.1073/pnas.96.12.6879, 22010, 10359807.
7. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738. 10.1038/nature01112, 12384702.
8. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002, 62:6178-6186.
9. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002, 169:4098-4102.
10. Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008, 68:6368-6376. 10.1158/0008-5472.CAN-07-6768, 18676862.
11. Liu G, Atteridge CL, Wang X, Lundgren AD, Wu JD. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J Immunol 184:3346-3350.
12. Hayakawa Y, Kelly JM, Westwood JA, Darcy PK, Diefenbach A, Raulet D, Smyth MJ. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 2002, 169:5377-5381.
13. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001, 413:165-171. 10.1038/35093109, 11557981.
14. Hidalgo M. Pancreatic cancer. N Engl J Med 362:1605-1617.
15. Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 2005, 54:915-925. 10.1007/s00262-004-0638-1, 15782312.
16. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996, 93:12445-12450. 10.1073/pnas.93.22.12445, 38011, 8901601.
17. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998, 279:1737-1740. 10.1126/science.279.5357.1737, 9497295.
18. Hue S, Monteiro RC, Berrih-Aknin S, Caillat-Zucman S. Potential role of NKG2D/MHC class I-related chain A interaction in intrathymic maturation of single-positive CD8 T cells. J Immunol 2003, 171:1909-1917.
19. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008, 93:4331-4341. 10.1210/jc.2008-1102, 2582569, 18713817.
20. Xu X, Rao G, Gaffud MJ, Ding HG, Maki G, Klingemann HG, Groh V, Spies T, Caillat-Zucman S, Gattuso P, Plate J, Prinz RA. Clinicopathologic significance of major histocompatibility complex class I-related chain A and B (MICA/B) expression in thyroid cancer. J Clin Endocrinol Metab 2006,
21. Marten A, von Lilienfeld-Toal M, Buchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer 2006, 119:2359-2365. 10.1002/ijc.22186, 16929491.
22. Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J, Sun W. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol
23. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Kimura R, Miyagi T, Mochizuki K, Sasaki Y, Hayashi N. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003, 104:354-361. 10.1002/ijc.10966, 12569559.
24. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 2003, 100:9452-9457. 10.1073/pnas.1632807100, 170939, 12878725.
25. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004, 114:560-568. 503776, 15314693.
26. Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001, 10:535-544. 10.1089/15258160152509145, 11522236.
27. Maki G, Klingemann HG, Martinson JA, Tam YK. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res 2001, 10:369-383. 10.1089/152581601750288975, 11454312.
28. Romanski A, Bug G, Becker S, Kampfmann M, Seifried E, Hoelzer D, Ottmann OG, Tonn T. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol 2005, 33:344-352. 10.1016/j.exphem.2004.11.006, 15730858.
29. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998, 95:4510-4515. 10.1073/pnas.95.8.4510, 22520, 9539768.
30. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, Weiss EH, Melms A, Weller M. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002, 168:4772-4780.
31. Menier C, Riteau B, Carosella ED, Rouas-Freiss N. MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int J Cancer 2002, 100:63-70. 10.1002/ijc.10460, 12115588.
32. Conejo-Garcia JR, Benencia F, Courreges MC, Gimotty PA, Khang E, Buckanovich RJ, Frauwirth KA, Zhang L, Katsaros D, Thompson CB, Levine B, Coukos G. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. Cancer Res 2004, 64:2175-2182. 10.1158/0008-5472.CAN-03-2194, 15026360.
33. Conejo-Garcia JR, Benencia F, Courreges MC, Khang E, Zhang L, Mohamed-Hadley A, Vinocur JM, Buckanovich RJ, Thompson CB, Levine B, Coukos G, Letal. A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol Ther 2003, 2:446-451.
34. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190. 10.1038/nature03884, 1352168, 15995699.
35. Kohga K, Takehara T, Tatsumi T, Miyagi T, Ishida H, Ohkawa K, Kanto T, Hiramatsu N, Hayashi N. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res 2009, 69:8050-8057. 10.1158/0008-5472.CAN-09-0789, 19826051.
36. Kim JY, Bae JH, Lee SH, Lee EY, Chung BS, Kim SH, Kang CD. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide. J Immunother 2008, 31:475-486. 10.1097/CJI.0b013e3181755deb, 18463537.
37. Armeanu S, Krusch M, Baltz KM, Weiss TS, Smirnow I, Steinle A, Lauer UM, Bitzer M, Salih HR. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res 2008, 14:3520-3528. 10.1158/1078-0432.CCR-07-4744, 18519785.
38. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008, 14:1455-1463. 10.1158/1078-0432.CCR-07-0371, 2879140, 18316569.
39. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009, 27:5911-5918. 10.1200/JCO.2009.23.3494, 2793039, 19805669.